Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 11/20 | 0.94 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.94 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.94 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartocin SCHEMBL29439933 | 1.00 | OXTR (0.94) | OXTRAVPR1AAVPR1BAVPR2 | |
| Aspartocin SCHEMBL2398841 | 1.00 | OXTR (0.94) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL19712185 | 0.98 | OXTR (0.90) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL122621 | 0.98 | OXTR (0.90) | OXTRAVPR1AAVPR1BAVPR2 | |
| Oxytocin SCHEMBL29048 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR1BAVPR2 | |
| Oxytocin SCHEMBL20707334 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL15512173 | 0.97 | OXTR (0.92) | OXTRAVPR1AAVPR1BAVPR2 | |
| Oxytocin SCHEMBL21527573 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR1BAVPR2 | |
| Oxytocin SCHEMBL1173243 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR1BAVPR2 | |
| Oxytocin SCHEMBL16373316 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR1BAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1453 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. | 2018-03-29 | — | — | US | claimed |
| CN-106821987-A | A kind of liposome and preparation method and application for carrying phenolic hydroxy group insoluble drug | 四川大学 | 2017-06-13 | — | — | CN | claimed |
| US-20160158261-A1 | Antibiotic Kit and Composition and Uses Thereof | FOAMIX LTD. (IL) | 2016-06-09 | — | — | US | claimed |
| US-9211259-B2 | Antibiotic kit and composition and uses thereof | FOAMIX PHARMACEUTICALS LTD. (IL) | 2015-12-15 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2013187954-A1 | MAGNETIC LABELING OF BACTERIA | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-19 | — | — | WO | claimed |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | LOS ALAMOS NAT SECURITY LLC (US) | 2013-09-26 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| EP-1355920-A1 | EXTRACTIVE PURIFICATION OF LIPOPEPTIDE ANTIBIOTICS | Micrologix Biotech, Inc. (CA) | 2003-10-29 | — | — | EP | claimed |
| US-20030125528-A1 | Process for preparing schiff base adducts of amines with o-hydroxy aldehydes and compositions of matter based thereon | HAY BRUCE A (US) | 2003-07-03 | — | — | US | claimed |
| EP-1311281-A1 | ANTIMICROBIAL SULFONAMIDE DERIVATIVES OF LIPOPEPTIDE ANTIBIOTICS | Micrologix Biotech, Inc. (CA) | 2003-05-21 | — | — | EP | claimed |
| EP-0524906-B1 | DNA coding for prolylendopeptidase and use thereof | NOVARTIS AG (CH) | 2003-04-16 | — | — | EP | claimed |
| US-20020132762-A1 | Extractive purification of lipopeptide antibiotics | BIOSOURCE PHARM, INC. | 2002-09-19 | — | — | US | claimed |
| WO-2002055537-A1 | EXTRACTIVE PURIFICATION OF LIPOPEPTIDE ANTIBIOTICS | INTRABIOTICS PHARMACEUTICALS, INC. (US) | 2002-07-18 | — | — | WO | claimed |
| US-20020028771-A1 | Antimicrobial sulfonamide derivatives of lipopeptide antibiotics | BIOSOURCE PHARM, INC. | 2002-03-07 | — | — | US | claimed |
| WO-2002005837-A1 | ANTIMICROBIAL SULFONAMIDE DERIVATIVES OF LIPOPEPTIDE ANTIBIOTICS | INTRABIOTICS PHARMACEUTICALS, INC. (US) | 2002-01-24 | — | — | WO | claimed |
| CN-1305490-A | Improved processing for preparing schift base adducts of amines with i(o)-hydroxy aldehydes and compositions of matter based thereon | PFIZER PROD INC (US) | 2001-07-25 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125528-A1 | Process for preparing schiff base adducts of amines with o-hydroxy aldehydes and compositions of matter based thereon | OGDH, ALDH7A1, AOX1 | OXTR 3362/4885AVPR1A 1970/4885AVPR1B 1040/4885 |
| US-20020028771-A1 | Antimicrobial sulfonamide derivatives of lipopeptide antibiotics | STS, CUTA, LSS | OXTR 3032/4885AVPR1A 3216/4885AVPR1B 4051/4885 |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | OXTR 1449/4885AVPR1A 663/4885AVPR1B 647/4885 |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | MCOLN1, PYM1, MCOLN2 | OXTR 1736/4885AVPR1A 854/4885AVPR1B 1093/4885 |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | OXTR 1449/4885AVPR1A 663/4885AVPR1B 647/4885 |
| US-20160158261-A1 | Antibiotic Kit and Composition and Uses Thereof | KIT, RAB5IF, CUTA | OXTR 164/4885AVPR1A 1782/4885AVPR1B 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.